Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2021-07-14 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE UK
Foreign Filer Report
2021-07-14 English
AstraZeneca-Alexion transaction cleared in the UK
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from AstraZeneca PLC, dated 14 July 2021. The content explicitly discusses receiving 'final regulatory clearance' for the acquisition of Alexion from the UK's Competition and Markets Authority (CMA) and details the expected closing date (21 July 2021) and subsequent stock exchange admissions/delistings. This is a specific corporate action announcement related to M&A activity (acquisition closing/regulatory hurdle clearance). While it relates to an acquisition (TAR), the format is a standard, time-sensitive regulatory news release disseminated via RNS, and it is not the full prospectus or merger agreement. Given the context of a general regulatory announcement about a major corporate event, and the presence of the RNS Number and the standard disclaimer language typical of market disclosures, the most appropriate primary classification is Regulatory Filings (RNS), as it serves as the official notification mechanism for such events that aren't strictly M&A documents (TAR) or financing updates (CAP). However, since the core subject is the final step of a major acquisition, it strongly relates to M&A Activity (TAR). Since the document is a formal announcement detailing the clearance of a merger condition, TAR is a strong candidate, but RNS is the delivery mechanism and a broad category for such time-sensitive news. Given the specific nature of the content (M&A clearance), TAR is more descriptive than the general RNS fallback. The document is long enough (17832 chars) that it is not just a brief 'Report Publication Announcement' (RPA). I will classify it as M&A Activity (TAR) because the entire substance is about the acquisition closing condition being met.
2021-07-14 English
425 Filing
Regulatory Filings
2021-07-14 English
425 Filing
Regulatory Filings
2021-07-14 English
TEZEPELUMAB GRANTED FDA PRIORITY REVIEW FOR ASTHMA
Foreign Filer Report
2021-07-08 English
Tezepelumab granted FDA Priority Review for asthma
Regulatory Filings Classification · 100% confidence The document is a formal announcement released via RNS (RNS Number : 5408E) on July 8, 2021. The content details a significant regulatory event: the FDA's acceptance and granting of Priority Review for AstraZeneca's Biologics License Application (BLA) for tezepelumab for asthma treatment. This is a specific, material corporate event announcement concerning regulatory progress and clinical trial data (NAVIGATOR, SOURCE). It is not a full Annual Report (10-K), an Interim Report (IR), or a general Earnings Release (ER). It is a specific regulatory/corporate update. Since it is a formal, time-sensitive announcement of a material event (FDA action), and it is distributed via RNS, it fits best under the general 'Regulatory Filings' category (RNS) as a specific regulatory update, although it contains elements of R&D/Clinical news. Given the options, RNS serves as the appropriate catch-all for specific, non-standard regulatory/exchange announcements that aren't covered by the other specific codes (like DIRS, DIV, etc.). The document length (17k chars) is substantial, suggesting it is the primary announcement itself, not just a brief notice of publication (RPA).
2021-07-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.